303 related articles for article (PubMed ID: 32972802)
41. [The Latest Research Progress of Selinexor in the Treatment of Non-Hodgkin Lymphoma --Review].
Tang XY; Wang Y; Xu RR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):292-296. PubMed ID: 36765514
[TBL] [Abstract][Full Text] [Related]
42. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
43. Selinexor: First Global Approval.
Syed YY
Drugs; 2019 Sep; 79(13):1485-1494. PubMed ID: 31429063
[TBL] [Abstract][Full Text] [Related]
44. The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.
Farren MR; Hennessey RC; Shakya R; Elnaggar O; Young G; Kendra K; Landesman Y; Elloul S; Crochiere M; Klebanov B; Kashyap T; Burd CE; Lesinski GB
Mol Cancer Ther; 2017 Mar; 16(3):417-427. PubMed ID: 28148715
[TBL] [Abstract][Full Text] [Related]
45. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
Jardin F; Pujals A; Pelletier L; Bohers E; Camus V; Mareschal S; Dubois S; Sola B; Ochmann M; Lemonnier F; Viailly PJ; Bertrand P; Maingonnat C; Traverse-Glehen A; Gaulard P; Damotte D; Delarue R; Haioun C; Argueta C; Landesman Y; Salles G; Jais JP; Figeac M; Copie-Bergman C; Molina TJ; Picquenot JM; Cornic M; Fest T; Milpied N; Lemasle E; Stamatoullas A; Moeller P; Dyer MJ; Sundstrom C; Bastard C; Tilly H; Leroy K
Am J Hematol; 2016 Sep; 91(9):923-30. PubMed ID: 27312795
[TBL] [Abstract][Full Text] [Related]
46. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
[TBL] [Abstract][Full Text] [Related]
47. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.
Parikh K; Cang S; Sekhri A; Liu D
J Hematol Oncol; 2014 Oct; 7():78. PubMed ID: 25316614
[TBL] [Abstract][Full Text] [Related]
48. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.
Durand M; Cabaud Gibouin V; Duplomb L; Salmi L; Caillot M; Sola B; Camus V; Jardin F; Garrido C; Jego G
J Exp Clin Cancer Res; 2024 May; 43(1):148. PubMed ID: 38773631
[TBL] [Abstract][Full Text] [Related]
49. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
[TBL] [Abstract][Full Text] [Related]
50. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
51. Selinexor for the treatment of patients with previously treated multiple myeloma.
Mo CC; Jagannath S; Chari A; Nooka AK; Lonial S; Siegel D; Biran N; Gasparetto C; Bahlis NJ; Richardson P
Expert Rev Hematol; 2021 Aug; 14(8):697-706. PubMed ID: 33985401
[TBL] [Abstract][Full Text] [Related]
52. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
[TBL] [Abstract][Full Text] [Related]
53. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
[TBL] [Abstract][Full Text] [Related]
54. Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity.
Martin JG; Ward JA; Feyertag F; Zhang L; Couvertier S; Guckian K; Huber KVM; Johnson DS
Chembiochem; 2021 Jun; 22(12):2116-2123. PubMed ID: 33887086
[TBL] [Abstract][Full Text] [Related]
55. Targeting nuclear import and export in hematological malignancies.
Nachmias B; Schimmer AD
Leukemia; 2020 Nov; 34(11):2875-2886. PubMed ID: 32624581
[TBL] [Abstract][Full Text] [Related]
56. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
[TBL] [Abstract][Full Text] [Related]
57. Clinical translation of nuclear export inhibitors in cancer.
Senapedis WT; Baloglu E; Landesman Y
Semin Cancer Biol; 2014 Aug; 27():74-86. PubMed ID: 24755012
[TBL] [Abstract][Full Text] [Related]
58. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
Rosebeck S; Alonge MM; Kandarpa M; Mayampurath A; Volchenboum SL; Jasielec J; Dytfeld D; Maxwell SP; Kraftson SJ; McCauley D; Shacham S; Kauffman M; Jakubowiak AJ
Mol Cancer Ther; 2016 Jan; 15(1):60-71. PubMed ID: 26637366
[TBL] [Abstract][Full Text] [Related]
59. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
[TBL] [Abstract][Full Text] [Related]
60. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D
Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
